Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genimous Technology Co Ltd
SZSE:000676
|
CN |
|
Suzhou TFC Optical Communication Co Ltd
SZSE:300394
|
CN |
|
Springsnow Food Group Co Ltd
SSE:605567
|
CN |
|
D
|
Digital Info Security Co
OTC:DGIF
|
US |
|
Wallenstam AB
STO:WALL B
|
SE |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (23.9), the stock would be worth ¥-1.26 (104% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -580.2 | ¥30.58 |
0%
|
| Industry Average | 23.9 | ¥-1.26 |
-104%
|
| Country Average | 28.8 | ¥-1.52 |
-105%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥13.4B
|
/ |
Oct 2025
¥-24.5m
|
= |
|
|
¥13.4B
|
/ |
Dec 2025
¥114.1m
|
= |
|
|
¥13.4B
|
/ |
Dec 2026
¥283.8m
|
= |
|
|
¥13.4B
|
/ |
Dec 2027
¥557.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
|
12.5B CNY | -580.2 | 1 712.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 27.7 | 40.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 16.6 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.1 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.3 | 19.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Shenzhen Chipscreen Biosciences Co Ltd
Glance View
In the bustling city of Shenzhen, often hailed as China's Silicon Valley, Shenzhen Chipscreen Biosciences Co Ltd stands as a testament to innovation in the biopharmaceutical landscape. Founded in 2001, the company embarked on a journey to bridge the gap between cutting-edge bioscience and market needs, focusing on research, development, and commercialization of novel drugs. Chipscreen’s core strength lies in its proprietary chemical genomics-based discovery and development platform, which has carved out a niche in identifying molecular targets and mining drug candidates with high therapeutic potential. The company seamlessly integrates advanced technologies with biotech prowess to design and develop small molecule drugs that address unmet clinical needs, primarily focusing on oncology, autoimmune diseases, and metabolic disorders. The financial engine of Chipscreen Biosciences hums through a well-orchestrated portfolio strategy. By progressing drug candidates through various stages of clinical trials, the company has not only diversified its offerings but also strategically positioned itself in lucrative therapeutic markets. Its revenue model capitalizes on successful product commercialization, primarily through sales of its marketed drugs and royalties from licensing agreements with strategic partners. This collaborative approach enables Chipscreen to maximize its product reach while sharing developmental risks. As the company's innovative therapies gain traction in domestic and global markets, Chipscreen continues its commitment to reinvest in research and development, crafting a sustainable cycle of growth fueled by scientific advancement and strategic acumen.
